Indian generics makers are on a roll. Yesterday, a Ranbaxy-Ipca Laboratories unit got the OK to make generic Metformin; today, a Sun Pharmaceuticals subsidiary won a tentative FDA for its version of Prandin, a type 2 diabetes drug originally made by Novo Nordisk.
Caraco Pharmaceutical Laboratories, based in Detroit, says it's first out of the chute with generic repaglinide, and it's hoping for 180-day marketing exclusivity. The approval is contingent on Caraco's resolution of any patent issues with Novo Nordisk, now under litigation.
- read the report from the Detroit Free Press
Related Articles:
Patent 'cliff' looms for Big Pharma. Report
Indian court spurns Novartis on patent challenge. Report
Generic competition slashes prices. Report
India's biotech future is bright. Report